Program

Preliminary Program. Subject to Changes & Updates.

TimeSession
08:00Welcome Coffee
08:45Opening Remarks – Organizers
08:50Keynote I: Mathias Vormehr – Senior Director Cancer Vaccines – BioNTech – “mRNA vaccines for the treatment of cancer”
09:30Company Presentations I:
Constance Ciaudo Beyer
– DeepLife – “Digital twin of cells for drug discovery”
Alice Ghidini – SENISCA – “Oligonucleotide senotherapeutics for the diseases of ageing
Dominik Witzigmann – NanoVation Therapeutics – “Next-generation LNP technologies to enable RNA delivery beyond the liver”
10:30Ingrid B. Müller – Swiss Federal Institute of Intellectual Property – “The Patent Landscape of RNA Therapeutics”
10:40Coffee Break
11:10Clinical RNA Therapeutics in Rare Diseases :
Matias Wagner – Institute of Human Genetics, Klinikum rechts der Isar, Technical University Munich – “A Novel Antisense Oligonucleotide for the Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy: A First-in-Patient Report in a Preterm Infant with Refractory Status Epilepticus”
11:35Panel – RNA Therapeutics – Future Developments:
Marc Abramowicz – Professor & Head, Genetic Medicine, University Hospital Geneva
Jasmin Barman-Aksözen – Triemli Hospital & University of Zurich
Matias Wagner – Institute of Human Genetics, Klinikum rechts der Isar, Technical University Munich
Annemieke Aartsma-Rus – Professor of Human Genetics – University of Leiden
Mathias Vormehr – Senior Director Cancer Vaccines – BioNTech
Moderated by Jonathan Hall
12:00Lunch & Poster Session & Networking & Sponsor Presentations
13:15 Lunchtalk: Clement Quan – Alithea Genomics – “RNA sequencing at scale: Next generation drug and biomarker discovery”
14:00Keynote II: Annemieke Aartsma-Rus – Professor of Human Genetics – University of Leiden – “From Duchenne exon skipping to N=1 treatment: Applying lessons learned for (very) rare disease patients”
14:40Young Scientists Career Talks:
Alice Ghidini – VP Oligotherapeutics Development – SENISCA – “Bridging Chemistry and Preclinical Development of RNA Therapeutics, with a biophysical perspective”
Larissa Grolimund – Global Regulatory Affairs CMC Manager – CSL Behring – “From RNA Lab to Regulatory Desk”
Mateusz Mendel – Senior Scientist Lead Discovery – Roche – “From RNA Biology to Drug Discovery: Navigating an Early Career in Industry”
15:00Translational Academic Projects
Felix Baier
– CALDRE & University of Bern – “Liver specific therapies to combat cholestatic diseases”
Algera Goga – University Children’s Hospital Zurich & University of Zurich – “Antisense oligonucleotides as splicing modulators for an N=1 trial of Arginase deficiency”
Rory Johnson – UC Dublin & University of Bern – “Linn Therapeutics: CRISPR-powered non-coding RNA therapeutics for oncology”
Raja Prince – BLEEDnFIRE Therapeutics & University of Bern “Advancing Hemophilia Care: siRNA Targeting Protein S for Optimal Hemostasis and Bone Health”
15:55Coffee Break
16:25
Company Presentations II
Troels Koch – MiNA Therapeutics – “MiNA therapeutics: Upregulating gene xpression”
Covadonga Pañeda – Altamira Therapeutics- “OligoPhore and SemaPhore for extrahepatic delivery of therapeutic RNA”
Keith Phillips – Grünenthal – “New Horizons in RNA Therapeutics: Unlocking Peripheral Neuronal Delivery to Target Chronic Pain and Sensory Disorders”
Felix Schumacher – Roche – “New developments in the delivery of therapeutic oligos to eye and brain”
17:35Keynote III: Eric Miska – Co-founder Storm Therapeutics & University of Cambridge, United Kingdom – “New ways of targeting and delivering RNA”
18:15Concluding Remarks – Organizers
18:20Apéro